Fda Advisory

• An FDA advisory panel narrowly voted to recommend allowing compounding pharmacies to produce BPC-157 and KPV, two popular but unproven peptides. • The decision follows advocacy from Robert F. Kennedy Jr., who pushed for increased access to these substances despite their lack of formal FDA approval. • This move is significant as it challenges standard regulatory hurdles for unapproved drugs, potentially expanding patient access to experimental treatments.

• An FDA advisory panel is meeting this week to determine if compounding pharmacies should be permitted to offer seven synthetic peptides. • The panel must weigh whether regulated compounding pharmacies provide a safer alternative to the "gray-market" versions currently used by enthusiasts. • The decision is critical due to significant concerns regarding the safety of these largely unproven peptides and potential conflicts of interest.

• An FDA advisory panel began a two-day meeting on Thursday to review more than six types of peptides currently used in wellness trends. • These substances are under scrutiny because there is little scientific evidence to prove they are safe or effective for human use. • The review is critical as these unproven peptides have gained popularity despite a lack of formal regulatory approval.